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Abstract:  
Background & Aims: The clinical effects of gluten-sensitive enteropathy with villous atrophy 
limited to the duodenal bulb (D1) have not been delineated in adults with celiac disease. We 
investigated the sensitivity of D1 biopsy analysis in detection of celiac disease, the number 
and sites of biopsies required to detect ultra-short celiac disease (USCD, villous atrophy 
limited to D1), and the clinical phenotype of USCD. 
 
Methods: We performed a prospective study of 1378 patients (mean age, 50.3 years; 62% 
female) who underwent endoscopy at a tertiary medical center in the United Kingdom from 
2008 through 2014; routine duodenal biopsies were collected from D1 and D2. Quadrantic 
D1 biopsies were collected from 171 consecutive patients with a high suspicion of celiac 
disease (mean age 46.5 years; 64% female). Clinical data from patients diagnosed with 
USCD, based on biopsy analysis, were compared with those from patients with conventional 
celiac disease (villous atrophy beyond D1) and individuals without celiac disease (controls). 
Numbers of intraepithelial lymphocytes (IELs) and immune phenotypes were compared 
between D1 vs D2 in patients with celiac disease.  
 
Results: Of the 1378 patients assessed, 268 (19.4%) were diagnosed with celiac disease; 
9.7% of these patients had villous atrophy confined to D1 (USCD, P<.0001). Collection of a 
single additional biopsy from any D1 site increased the sensitivity of celiac disease detection 
by 9.3% ?10.8% (P<.0001). Patients with USCD were younger (P=0.03), had lower titers of 
tissue transglutaminase antibody (P=.001), and less frequently presented with diarrhea 
(P=0.001) than patients with conventional celiac disease. Higher proportions of patients 
with conventional celiac disease had ferritin deficiency (P=.007) or folate deficiency 
(P=0.003) than of patients with USCD or controls.  Patients with celiac disease had median 
50 IELs/100 enterocytes in D1 and a median 48 IELs/100 enterocytes (P=.7) in D2. The 
phenotype of IELs from patients with D1 celiac disease was indistinguishable from those of 
patients with D2 celiac disease. 
Conclusions: Collection of a single additional biopsy from any site in the D1 intestine 
increases the sensitivity of detection for celiac disease. Patients with USCD may have early-
stage or limited celiac disease, with a mild clinical phenotype and infrequent nutritional 
deficiencies. 
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Introduction 
Internationally the prevalence of celiac disease is now recognised to be 0.2-1.0%.
1-3
 
However, despite increased awareness, celiac disease remains under-diagnosed. A recent 
UK study demonstrated that only 1 in 4 patients with celiac disease are currently 
diagnosed.
4
 Cohorts from the international literature have reported significant delays in 
diagnosis ranging from 4 to 13 years.
5, 6
 Furthermore 5-13.6% of patients with newly 
diagnosed celiac disease have had a prior endoscopy where the chance to diagnose celiac 
disease was missed.
5, 7
 In many patients no consideration was given to duodenal biopsy 
however 41% of patients in a recent US study had a non-diagnostic duodenal biopsy.
7
 
Historically small bowel biopsies were taken from the jejunum with a Crosby capsule to 
diagnose celiac disease.
8
 However with the advent of fibre-optic endoscopy biopsies from 
the distal duodenum were shown to be as accurate as jejunal biopsies for recognising celiac 
disease.
8
 The gluten load is highest in the proximal GI tract and the duodenal bulb (D1) 
would seem a logical place to identify signs of celiac disease. However D1 had been avoided 
as a possible biopsy site due to concerns over the difficulty in interpretation due to the 
ƉŽƚĞŶƚŝĂůƉƌĞƐĞŶĐĞŽĨƌƵŶŶĞƌ ?ƐŐůĂŶĚƐ ?ŐĂƐƚƌŝĐŵĞƚĂƉůĂƐŝ  ?ƉĞƉƚŝĐĚƵŽĚĞŶŝƚŝƐĂŶĚƉƌĞƐƵŵĞĚ
reduced villous height.
9
 Prospective data from a heterogeneous group of small studies has 
suggested that interpretation of D1 biopsies is possible and may be the only site of villous 
atrophy in newly diagnosed celiac disease, (ultra-short celiac disease, (USCD)) (Table 1).
8-13
 
D1 biopsy however is not yet fully accepted for several reasons. Firstly, the majority of these 
studies are based on small cohorts with inadequate control groups used. The number of 
adult cases of USCD described from these endoscopy based studies totals only 25. Thus the 
international experience of this condition is very limited. Data published globally have been 
geared around establishing if a duodenal bulb biopsy should be taken and the potential for 
increased diagnostic yield.  It has not been established if D1 biopsy is necessary for all 
indications. Secondly, the ideal number and site for D1 biopsy in new cases has not been 
fully established. This has only been evaluated in a single small cohort of 28 patients where 
it was suggested that ďŝŽƉƐŝĞƐĨƌŽŵƚŚĞ ?K ?ĐůŽĐŬĂŶĚ ? ?K ?ĐůŽĐŬƉŽƐŝƚŝŽŶƐŵĂǇďĞŽƉƚŝŵĂů ?11 
Thirdly, it is not clear if the histology of D1 in celiac disease is equivalent to D2. Indeed a 
recent study has suggested that the normal count of intraepithelial lymphocytes (IELs) in 
healthy patients may be lower in D1 than D2.
14
 To date there are no data assessing 
histological phenotype in D1 in celiac disease. Finally, crucially it has not been established if 
USCD represents the same clinical phenotype and has the same implications as more 
extensive, conventional celiac disease including long-term outcomes. 
We aimed therefore, to establish the prevalence of USCD, in the largest patient cohort 
reported internationally, in the context of a routine duodenal biopsy strategy in all-comers 
to open-access diagnostic gastroscopy. We aimed to assess the ideal number and site of 
bulb biopsy for detection of USCD. Furthermore, we aimed to establish the clinical and 
histological phenotype of USCD. 
Methods 
Patients were prospectively recruited from a single teaching hospital in Sheffield, UK, 
between 2008 and 2014.  Consecutive patients attending a single research endoscopy list, 
where routine duodenal biopsy is employed, were recruited in a significant expansion of our 
previous study of 376 patients.
12
 Patients attending include those with suspected celiac 
disease but also include general and open access referrals for all upper GI symptoms. All 
recruited patients received quadrantic biopsies from the second part of the duodenum. At 
least one further biopsy sample was taken from D1 in a separate formalin pot.  
 
Within this cohort, in an expansion of our previously reported study 
11
, consecutive patients 
with a high clinical suspicion of celiac disease had standardised quadrantic biopsies taken 
from D1 in addition to the distal duodenum to identify the ideal number and site for D1 
biopsy. In these patients the different topographic areas from which the quadrantic bulb 
biopsy specimens were taken correlating with a clock face.  Specimens were taken from the 
 ? ? K ?ĐůŽĐŬ ?  ? K ?ĐůŽĐŬ ?  ? K ?ĐůŽĐŬ ĂŶĚ  ? K ?ĐůŽĐŬ ƉŽƐŝƚŝ ŶƐ ǁŝƚŚŝŶ  ? ? ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚ
positioned in the left lateral position. This ensured biopsies were aimed at targeted areas 
rather than specifically to areas of obvious mucosal abnormality and allowed consistency of 
sampling between patients. Biopsy specimens from D1 were carefully inserted into a biopsy 
cassette with numbered compartments, reflecting specific D1 biopsy sites, before being 
fixed in formalin at the time of endoscopy. Each of the bulb specimens was placed in a 
separate paraffin wax block. All 4 of the biopsies from the distal duodenum were orientated 
and embedded in a single block of paraffin wax by the pathology department. ^ƚĂŶĚĂƌĚ ?ʅŵ
thick sections were taken from all samples and stained with hemotoxylin and eosin. Distal 
D2 biopsy specimens were analysed prior to bulb biopsy specimens. Each of the biopsy 
specimens was graded according to the modified Marsh criteria, to identify the presence 
and severity of villous atrophy. The Marsh criteria were applied consistently between the 
bulb and distal duodenum. We have 6 gastrointestinal pathologists who all routinely initially 
reported duodenal biopsies that were undertaken during the course of the study. Validation 
was then performed by 2 of these pathologists independently reviewing both USCD and 
conventional celiac disease cases. All patients enrolled received concurrent standard celiac 
serology tests, as well as immunoglobulins, taken on the day of their examination. IgA tissue 
transglutaminase (tTG) was measured by using a single enzyme-linked immunosorbent 
assay (Aesku Diagnostics, Wendelsheim, Germany). A tTG titer of greater than 15 U/mL was 
ƵƐĞĚ ƚŽ ĚĞĨŝŶĞ Ă ƉŽƐŝƚŝǀĞ ƚĞƐƚ ĂƐ ƉĞƌ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ? /Ő ĞŶĚŽŵǇƐŝĂů
antibody (EMA) was detected by immunofluorescence on primate oesophagus sections 
(Binding Site, Birmingham, UK). Total immunoglobulins were measured on a Behring BN2 
nephelometer (Dade Behring, Marburg, Germany). Patients were excluded from the study if 
they had any standard contraindications to endoscopic biopsy, if they had active 
gastrointestinal bleeding, if a suspected carcinoma was observed during the examination, or 
if they were pregnant. 
Patients were defined as having celiac disease if they had the combination of positive 
antibodies (EMA or tTG) and evidence of increased IELs, crypt hyperplasia and villous 
atrophy, (Marsh 3a ?3c) in any of their biopsy specimens. For cases of villous atrophy in 
which the patient had negative celiac serology, supporting evidence of celiac disease was 
sought including, family history, exclusion of other causes of villous atrophy, gluten 
challenge, repeat biopsy and/or response to a gluten free diet. All patients with villous 
atrophy confined to D1 had their HLA status checked with HLA DQ2 or DQ8 required for 
diagnosis. 
To ascertain the phenotype and consequences of USCD patients were split into 4 groups 
based on histology findings. Group 1 was comprised of the patients diagnosed with USCD and 
they were compared to patients with conventional celiac disease (Group 2) and the remaining 
patients who were not diagnosed with celiac disease (Group 3). Presenting symptoms and 
serology taken at the time of endoscopy were compared across the whole cohort (Groups 1,2 
and 3). A fourth group (Group 4) was identified to compare baseline hematology, 
biochemistry, bone profile and hematinics taken prior to commencing gluten free diet. These 
patients were age and sex matched controls identified from within Group 3 who had negative 
EMA and tTG and normal duodenal histology.  Baseline bone densitometry using Dual-energy 
X-ray Absorptiometry (DXA) was also compared between groups 1 and 2. Osteopenia was 
defined as a T-score of -1.5 to -2.4 and osteoporosis as a T-score of less than -2.5. Blinded IEL 
counts were performed in 25 consecutive patients with celiac disease and compared to age 
and sex matched controls with negative serology. Counts were made manually using Image-J 
software (National Institutes of Health) on sections stained with hemotoxylin and eosin. 
Median IEL counts per 100 enterocytes were calculated from 5 representative villi using the 
previously validated method of Walker and colleagues.
15
 In cases with villous atrophy IELs 
were counted for 50 enterocytes starting mid-way between 2 crypts in 5 separate sites.   
Immunohistochemistry staining for CD3, CD4 and CD8 was used in patients with villous 
atrophy in both D1 and D2 to assess for any phenotypic differences.  
Follow up 
All patients diagnosed with USCD and conventional celiac disease received specialist dietetic 
advice on the gluten free diet. Subsequently patients were invited to attend for repeat clinical 
evaluation 9-18 months following institution of a gluten free diet. Bloods for repeat serology, 
hematology, biochemistry and hematinics were taken. Dietary adherence was estimated 
using a previously validated 5 point questionnaire.
16
 Patients graded any change in symptoms 
since institution of a gluten free diet using a likert scale graded from -10 to +10. On this scale 
0 represented no improvement in symptoms -10 representing a significant deterioration in 
symptoms and +10 a significant improvement in symptoms.   
Statistical analysis  
The sensitivity for duodenal biopsy sites were compared using a McNemar test for 
correlated proportions. Univariate analysis of categorical presenting characteristics between 
USCD, conventional celiac disease and control patients was performed using Chi square. 
Multivariate analysis, correcting for age, gender and concurrent presenting symptoms, was 
performed using binary and multinomial logistic regression. Chi-squared Automatic 
Interaction Detector (CHAID) decision tree analysis was used to identify groups likely to be 
diagnosed with USCD or conventional celiac disease. The CHAID decision tree model uses 
multiple Chi-square tests corrected for multiple comparisons (Bonferroni) to identify the 
most significant independent variable. Once this has been identified the model splits 
subjects into groups based on this variable and further analysis is carried out in each of the 
new groups. A p value <0.05 was required for splitting of nodes and we chose an unlimited 
tree depth. The Kruskal-Wallis test was used for comparing non-parametric continuous 
values and ANOVA was used for parametric data to analyse the consequences of USCD and 
conventional celiac disease compared to controls. Absolute values were compared using a 
Chi-square. Follow up data were compared using a paired Wilcoxon sign-rank test for non-
parametric data and a paired students t-test for parametric data. Analysis was undertaken 
using SPSS 21.0 (IBM). All p values provided are 2 sided. 
 
Ethical considerations 
Ethical approval of the study was sought and gained from the local National Health Service 
Research and Ethics Committee under the study number STH15416. All patients consented 
to their procedures in accordance with the UK Joint Advisory Group for endoscopy 
guidelines. 
Results 
Patients 
In total 1378 patients (mean age 50.3, 62% female) were consecutively recruited. Dyspepsia 
and diarrhea were the most frequent reasons for referral for endoscopy in 328 (27.6%) and 
221 (16.0%) patients respectively. A full list of presenting complaints is shown in table 2. Of 
1378 patients, 423 (30.7%) had a positive serological test taken at the time of endoscopy 
and 154 patients (11.1%) had previous equivocal duodenal histology (seronegative villous 
atrophy or raised IELs). This represents a referral bias as we are a centre with a specialist 
interest in celiac disease.  
In total 268 patients (19.4%) were newly diagnosed with celiac disease. Multivariate analysis 
revealed a diagnosis of celiac disease was associated with younger age (P<0.0001), anemia 
(AOR 1.71, P=0.02), a family history of celiac disease (AOR 2.89, P<0.0001), lethargy (AOR 
3.67, P<0.0001) and osteoporosis (AOR 6.14, P<0.0001).  Celiac disease was not associated 
with reflux (AOR 0.10, p<0.0001) and non-specific dyspepsia (AOR 0.23 P<0.0001). Of 154 
patients referred with previously abnormal duodenal histology 17 (11.0%) were ultimately 
diagnosed with celiac disease. 
Is there an increased diagnostic yield with D1 sampling? 
Of the 268 patients diagnosed with celiac disease 26 had villous atrophy confined to D1 and 
were diagnosed with USCD. All of these patients had an HLA type compatible with celiac 
disease (19 DQ2 heterozygous; 5 DQ2 homozygous; 2 DQ8 heterozygous). By taking an 
additional D1 biopsy, therefore, the diagnostic yield was increased by 9.7% compared to 
standard D2 biopsy (P<0.0001). Of the 26 patients with villous atrophy confined to D1 7 
(26.9%) had entirely normal D2 biopsies whilst 18 (69.2%) had Marsh 1 changes and a single 
patient (3.8%) had Marsh 2 changes in D2. 
Non-celiac abnormalities were seen in 80 (5.8%) D1 biopsies. The most common histological 
abnormality other than celiac disease was peptic duodenitis which was seen in 4.1% of D1 
samples compared to 1.4% of D2 samples (PA? ? ? ? ? ? ? ? ? ƌƵŶŶĞƌ ?Ɛ ŐůĂŶĚƐ ŝŶƚĞƌĨĞƌŝŶŐ ǁŝƚŚ
interpretation was rare, but was seen more commonly in D1 (1.2%) compared to D2 (0.3%) 
samples (P=0.002). In total 24 patients (9.0%) were diagnosed with seronegative celiac 
disease. Importantly seronegative celiac disease was not more common in USCD (2/26, 7.7%) 
compared to conventional (22/242, 9.1%) (P=1.0). In the 2 cases of seronegative USCD one 
had a previously raised tTG and was HLA DQ2 heterozygous and the other patient presented 
with ataxia, had repeat biopsy confirming villous atrophy and was HLA DQ2 homozygous.  A 
diagnosis of seronegative celiac disease was only made in all cases after confirming an 
appropriate HLA type and a thorough re-examination looking for alternative causes of villous 
atrophy.  
Is there an optimal site for targeted D1 biopsy sampling? 
In total 171 patients (mean age 46.5, 64% female) recruited underwent quadrantic D1 biopsy. 
Of these, 65 patients (38%) were diagnosed with celiac disease and the remaining 106 (62%) 
patients served as controls. Villous atrophy was seen in D1 in 62 (95.4%) patients and D1 was 
the only site of villous atrophy in 7 patients (10.8%). Of the 62 patients with villous atrophy in 
D1, 6 (9.7%) had at least one D1 sample that showed no evidence of villous atrophy and in 23 
(37.1%) there was a difference between the Marsh grades. A D1 biopsy taken from the 3 
K ?ĐůŽĐŬƉŽƐŝƚŝŽŶŝŶĂĚĚŝƚŝŽŶƚŽƐƚĂŶĚĂƌĚ ?ďŝŽƉƐǇƌĞƐƵůƚĞĚŝŶ ? ? ?A?ƐĞŶƐŝƚŝǀŝƚǇ ?,ŽǁĞǀĞƌƚŚĞ
addition of biopsies from any of the other topographical areas each only resulted in missing 
of a single case. There was no significant difference between the sites however the addition 
of a D1 biopsy from any site was superior to a distal duodenal biopsy alone, increasing the 
diagnostic yield by 9.3-10.8% (P<0.0001). The sensitivity of quadrantic D1 biopsy without D2 
biopsy was 95.4% which was not statistically superior to D2 biopsy alone (P=0.34).  
Are there any consequences to Ultra-short Celiac Disease? 
In Group 1, 26 patients (mean age 37.3, 73% female) were diagnosed with USCD. Group 2 
comprised of 242 patients (mean age 42.0, 66% female) with conventional celiac disease. 
Group 3 comprised of the remaining 1,110 patients who did not have celiac disease. Group 4 
included 136 controls (mean age 42.3, 66% female) with negative EMA and tTG and normal 
duodenal histology to compare hematology and biochemistry values. Patients in diagnosed 
with celiac disease (Groups 1 and 2) were significantly younger than those without celiac 
disease (Group 3, P<0.0001). Interestingly, patients with USCD (Group 1) were younger than 
those diagnosed with conventional celiac disease (Group 2) (mean age 37.3 vs. 42.0, AOR 0.97 
(0.94  ? 0.998), P=0.03). On univariate analysis (table 2) patients with both USCD (Group 1) 
and conventional disease (Group 2) were less likely than controls (Group 3) to present with 
reflux (P<0.0001) or dyspepsia (P<0.0001) and more likely to have a family history of celiac 
disease (P<0.0001). Only 3.8% of USCD patients had diarrhea which was significantly lower 
than 24.1% of conventional celiac patients (P<0.0001). Furthermore on CHAID decision tree 
analysis (Bonferroni method) with unlimited tree depth to identify USCD amongst celiac 
patients the absence of diarrhea was the single discriminating factor (Adj P=0.019) (not 
shown). On multivariate analysis (table 3) conventional celiac patients but not USCD patients 
were more likely than controls to present with anemia, diarrhea, a family history of celiac 
disease, lethargy, and osteoporosis. CHAID analysis reveals the most significant diagnostic 
yield, at 49.3%, in our cohort was for patients with a family history of celiac disease 
presenting without dyspeptic symptoms. The full decision tree for diagnosing all patients with 
celiac disease based on symptomatic presentation is shown in figure 1.  
Patients with USCD (Group 1) had lower tTG titers (P=0.001) but had equal rates of tTG 
positivity (P=0.57) compared to conventional celiac disease (Group 2). The prevalence of 
ferritin deficiency was higher in conventional celiac disease (Group 2, 31.5%) than USCD 
(Group 1, 13.6%) and controls (Group 4, 16.7%) (P=0.007). The prevalence of folate deficiency 
was higher in conventional celiac disease (Group 2, 18.0%) than USCD (Group 1, 3.8%) and 
controls (Group 4, 6.3%) (P=0.003) There was no difference in bone densitometry findings 
between Groups 1 and 2. On multinomial logistic regression analysis tTG levels were 
confirmed to be lower in USCD (Group 1, AOR 0.91 (0.84 - 0.98) P=0.019) and folate levels 
were higher (AOR 1.17 (1.03 - 1.35) P=0.018) compared to conventional celiac disease (Group 
2).  A summary of the blood and DXA findings is shown in tables 4 and 5. 
Median IEL counts in patients without celiac disease were lower in D1 (11) than D2 (16) 
(P=0.002) however all median IEL counts were below the currently agreed cut off of 25 
IELs/100 enterocytes.
15
 In celiac disease the median IEL count in D1 was 50 and in D2 was 48 
(P=0.71). IELs in D1 were immunophenotypically indistinguishable to those in D2 in celiac 
patients.  
Follow up 
Follow up data were available for 24/26 patients with USCD. Two patients were lost to follow 
up, despite repeated attempts to contact them, following their initial clinic visit and dietetic 
support. Patients with USCD (Group 1) demonstrated a significant decrease in their tTG 
(P=0.006) after a median of 16 months on a gluten free diet. A statistically significant increase 
in corrected calcium was also identified (P=0.03). There was no significant change in the other 
hematology or biochemistry parameters assessed. This is in contrast to patients with 
conventional celiac disease (Group 2) who, after a median of 15 months on gluten free diet, 
demonstrated a significant increase in folate (P=0.001), ferritin (P<0.0001) and B12 
(P<0.0001) levels as well as a significant reduction in their tTG titers (P<0.0001). There was no 
significant difference in any follow up blood values between patients with USCD (Group 1) 
and conventional disease (Group 2). A full analysis of the follow up bloods is shown in table 6. 
On analysis of symptoms, the majority of patients with USCD disease noted an improvement 
with only a single patient complaining of deterioration in their symptoms (score -1). There 
was no significant difference between the median symptom improvement scores between 
USCD and conventional celiac disease patients on a gluten free diet (median score +6 for both 
groups p=0.67).  Interestingly rates of adherence based on the Biagi adherence score were 
marginally lower in the USCD patients (Group 1) compared to conventional disease (Group 2) 
(median 3 vs 4, P=0.02). This may be a representation of the more significant initial symptoms 
seen in the patients with conventional celiac disease.  
Discussion 
We have shown a significant increase in the diagnostic yield for celiac disease when a single 
D1 biopsy is taken from any site. Critically this is the first study to assess the clinical 
implications and presentation of USCD in adult patients. Our findings would support a 
hypothesis that patients with USCD represent early celiac disease with a milder clinical 
phenotype presenting at a younger age with more infrequent nutritional deficiencies. 
There is a growing body of evidence suggesting that D1 may be the only site of villous 
atrophy in patients with newly diagnosed celiac disease.
8-12
 However the practice of D1 
biopsy has not been universally accepted. Indeed, in a recent audit of non-specialist 
hospitals in the UK, a D1 biopsy was performed in only 18/914 (2.0%) of patients undergoing 
duodenal biopsy to diagnose celiac disease and only in 10% of patients in a recent US 
study.
17, 18
 There may be several reasons for the poor uptake in D1 biopsy which we have 
been able to address in this study. Firstly the numbers of patients have been very small with 
only 25 patients described frequently in highly celiac enriched populations with few if any 
control patients. In our study 1378 patients were prospectively recruited, more than twice 
the combined number of patients in previous adult studies. Furthermore all patients had 
routine duodenal biopsy performed reducing potential ascertainment bias within our cohort 
and increasing the applicability to the general population. Secondly there remain concerns 
that interpretation may be impeded by the presence of non-celiac abnormalities such as 
peptic duodenitis or gastric heterotopia. However in our cohort non-celiac abnormalities 
were relatively rare and were rarely considered to interfere with interpretation of duodenal 
biopsies. There are also concerns around the cost and time burden of additional duodenal 
biopsy. In our cohort only one biopsy was required from any site in D1 to significantly 
increase the sensitivity of duodenal biopsy. This has important implications as adopting a D1 
biopsy policy becomes more feasible if no specific area is required to be targeted. This may 
be in contrast to the only previous study into targeted bulb biopsy that suggested a 2 biopsy 
strategy fƌŽŵďŽƚŚƚŚĞ ?Ž ?ĐůŽĐŬŽƌ  ? ?Ž ?ĐůŽĐŬƉŽƐŝƚŝŽŶƐ ŝŶĐŽ ũƵŶĐƚŝŽŶǁŝƚŚƋƵĂĚƌĂŶƚŝĐ ?
biopsies may be optimal. In this small cohort this ensured that the most severe lesion was 
detected in 100% of cases. However, in our present study, only a 4 biopsy strategy ensured 
that the most severe lesion was seen in 100% of cases. In our opinion, although identifying 
the most severe lesion may be ideal, identification evidence of villous atrophy of any grade 
may be the most important diagnostic criterion. Further study may be required to identify 
the significance of severity of D1 atrophy.  
Finally none of the studies performed in adult patients have analysed the presentation of 
patients with USCD. Only a single pediatric study has assessed clinical characteristics.
19
 In a 
retrospective study of 101 children with newly diagnosed celiac disease, no differences in 
the mode of presentation USCD (n=10) and conventional disease could be elicited however 
the study was likely to be underpowered to detect significant differences. Furthermore no 
studies have attempted to assess the clinical impact of USCD. In our cohort patients with 
appeared to have a less severe clinical phenotype with less frequent diarrhea and fewer 
micronutrient deficiencies. This may be commensurate with the minimal loss of absorptive 
capacity associated with only a short segment of villous atrophy. Interestingly, however, 
patients with USCD were diagnosed at a younger age and had lower tTG titres suggesting 
that celiac disease may have been identified at an earlier stage. This may have resulted in 
fewer nutritional deficiencies from a shorter lead time to diagnosis. Furthermore, this may 
have other significant implications for patients allowing earlier intervention with a gluten 
free diet. This may ameliorate symptoms and reduce the burden of unnecessary 
investigations that can be associated with a missed celiac diagnosis.
7
 Furthermore it may 
also reduce the potential for long term sequelae of celiac disease such as lymphoma or 
osteoporosis. However, further long term follow up studies of patients with USCD are 
required to truly assess the long term implications of diagnosis.  
If it is true that histological changes of celiac disease are confined to D1 it may be difficult to 
account for any symptoms or deficiencies in the USCD group. There may be several reasons 
for this apparent paradox. Firstly our patient population may also have influenced our 
results. This was a study of patients attending endoscopy for investigation of symptoms or 
other known associations with celiac disease so patients were inherently more likely to have 
symptoms. It is conceivable that if we had conducted a screening study a diagnosis of USCD 
may have been associated with a higher proportion of asymptomatic patients.  
Secondly it is possible that in some of the USCD patients the diagnosis may have been 
missed in the biopsies taken from D2. This is certainly feasible given that celiac disease is 
recognized to be patchy. However the patients in our study all had adequate D2 biopsy 
(mean = 4.5) as recommended by international guidelines. Despite this, it is conceivable that 
the diagnosis could have been made by more extensive D2 biopsy or deeper duodenal or 
jejunal biopsy. However, in a previous study to identify the best site for D2 biopsy, even 
when 8 biopsies were routinely taken in distinct topographic areas in the proximal and distal 
D2 100% sensitivity for villous atrophy could only be achieved when a duodenal bulb biopsy 
was included.
8
 Studies of deeper duodenal or jejunal biopsy are fairly limited. A 2014 study 
of 41 pediatric patients showed 1 (2.4%) had villous atrophy in the jejunum only.
20
 A 
historical study from our center of 31 patients with a previously non-diagnostic duodenal 
biopsy found that 3 of the 5 patients who had celiac disease confirmed had disease limited 
to the jejunum, however no duodenal bulb biopsies were taken in any of these patients.
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Furthermore the gluten load is known to be highest in the proximal small bowel and there is 
evidence that the small bowel heals distally to proximally on a gluten free diet.
22, 23
 Some of 
the patients USCD group had Marsh 1 and 2 changes in more distal biopsies. These patients 
could be considered to belong to the celiac disease spectrum however these changes are 
non-specific. Indeed other prospective studies have subsequently confirmed celiac disease 
in only 16% of unselected patients 
24
 and 43.3% of patients with HLA DQ2 or DQ8.
25
 
Furthermore much of the evidence for the diagnosis of celiac disease based on Marsh 1 
changes alone is based on a single study of just 23 EMA positive patients.
26
  This cohort of 
patients demonstrated significant improvement in symptoms and antibody titers on a 
gluten free diet. Importantly the bulb was not biopsied in this study and had it been then it 
is conceivable the USCD may have been present in these patients. Furthermore this study 
has not had the impact of changing clinical practice because clinicians wish to see the 
presence of villous atrophy before committing a patient to a lifelong gluten free diet. As a 
result patients with a Marsh 1 lesion in D2 frequently undergo re-evaluation with prolonged 
gluten challenge and further invasive procedures to confirm or refute a diagnosis of celiac 
disease. It could be argued that by taking a duodenal bulb biopsy this could be avoided in a 
significant number of patients if villous atrophy is confirmed in the duodenal bulb. 
Importantly in our cohort 7/26 (26.9%) patients had completely normal D2 biopsies, and a 
further 4/26 (15.4%) patients had a negative EMA. If a duodenal bulb biopsy had not been 
performed then a diagnosis of celiac disease could have been missed in 11/26 (42.3%) of our 
cohort. Finally, another possibility is that symptoms and reduced bone mineral density in 
the USCD group are as a result of chronic inflammation or co-existent disease. This 
hypothesis is further strengthened by the fact that there was a significantly increased rate of 
autoimmune disease (1 psoriasis, 2 autoimmune thyroid disease, and 1 sjögrens) seen in the 
USCD group compared to the conventional disease group.  
One concern over the diagnosis of USCD is whether or not a strict gluten free diet is 
required for these patients. Some of these concerns appear to be validated by our present 
study as there is evidence of a milder clinical phenotype associated with fewer 
micronutrient deficiencies. However our follow up data have shown that the majority of 
patients have symptomatic improvement on a gluten free diet. Furthermore there is a 
significant drop in the tTG titer on institution of a gluten free diet. This would appear to 
suggest that the immune cascade has been switched off. Our hypothesis is that as patients 
are diagnosed significantly younger than those with conventional disease that this may 
present a unique opportunity to prevent further micronutrient deficiency in this select 
group of patients. Although there is no current evidence for this in USCD there is some 
supporting evidence from patients with Marsh 1 and 2 enteropathy. Patients with a positive 
EMA and Marsh 1 and 2 changes, from a Finnish cohort, were randomised to gluten free or 
gluten containing arms of the study. Histology significantly deteriorated in all patients who 
remained on a gluten containing diet.
26
 Perhaps USCD represents the next step in the 
development of a more extensive enteropathy. Further study may identify which patients 
require long term follow up for now however USCD and conventional celiac disease patients 
should be treated as part of the spectrum of the same disease and receive standard follow 
up.   
There are some potential limitations to our study. Firstly prevalence of celiac disease in our 
cohort was higher than might be expected for a routine endoscopy list. This was as a result 
of a referral bias to a centre with a specialist interest in celiac disease. This may have 
resulted in an overestimate of the prevalence of celiac disease in some patient groups 
however rates of celiac disease in different patient cohorts are similar to previous case 
finding studies reported in the literature.
27-29
 Furthermore this increased prevalence did 
allow us to accrue significant numbers of patients with USCD to allow for effective 
comparison of patient phenotypes. 
In conclusion, a single additional D1 biopsy from any site increases the diagnostic yield. A 
diagnosis of USCD may represent early celiac disease with a mild clinical phenotype. The 
addition of a D1 biopsy to diagnose celiac disease may reduce the known delay in diagnosis 
that many patients with celiac disease experience. This may allow earlier institution of a 
gluten free diet and potentially prevent nutritional deficiencies and reduce the symptomatic 
burden of celiac disease. 
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Table 1: A summary of the available studies into duodenal bulb biopsies for diagnosing celiac disease 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Univariate analysis of proportion of patients in each group with different 
presenting characteristics (percentages with different superscript letters are significantly 
different at a P<0.01 level) 
Presenting characteristic 
Total % 
(n=1378) 
USCD 
% 
(n=26)  
Conventional 
celiac 
disease % 
(n=242)   
Controls 
% 
(n=1110) P 
Female Gender 62.2 73.1 65.6 61.2 0.231 
Abdominal pain 13.2 3.8 12.0 13.7 0.287 
Alternating bowel habit 2.6 11.5
a
 3.3
b
 2.3
b
 0.010 
Anemia 12.5 19.2
a,b
 18.7
b
 11.0
a
 0.003 
Autoimmunity 4.4 15.4
a
 6.2
a,b
 3.8
b
 0.006 
B12/folate/vitamin D deficiency 4.9 7.7 7.5 4.2 0.084 
Year Country Adults / 
Pediatrics 
Number of 
patients  
Number of 
celiac 
disease (%) 
Number of 
USCD (%) 
2001 
10
 Austria Adults 51  21 (41.2%) 2 (9.5%) 
2004 
30
 Italy Pediatrics 95  95 (100%) 4 (4.2%) 
2005 
31
 Italy Adults 1  1 (100%) 1 (100%) 
2008 
8
 UK Adults 56  56 (100%) 1 (1.8%) 
2008 
32
 Italy Pediatrics 1013  665 (65.6%) 16 (2.4%) 
2009 
33
 Canada Pediatrics 35  29 (81.6%) 3 (11.4%) 
2010 
19
 USA Pediatrics 198 198 (100%) 10 (5.1%) 
2010 
34
 Italy Pediatrics 47 42 (89.4%) 5 (11.9%) 
2010 
9
 USA Adults 80 40 (50%) 5 (12.5%) 
2011 
35
 Israel Pediatrics 87 87 (100%) 6 (7.0%) 
2011 
12
 UK Adults 376 126 (33.5%) 11 (9.0%) 
2012 
11
 UK Adults 77 28 (36.4%) 5 (17.9%) 
2013 
36
 Australia Pediatrics 101 101 (100%) 8 (7.92%) 
2014 
13
 Italy Adults 42 25 (59.5%) 0 (0%) 
Bloating 7.8 7.7 10.4 7.2 0.249 
Diarrhoea 16.0 3.8
a
 24.1
b
 14.6
a
 <0.0001 
Dyspepsia 27.6 7.7
a
 5.0
a
 32.9
b
 <0.0001 
Family History 5.6 11.5
a
 14.5
a
 3.5
b
 <0.0001 
Irritable Bowel Syndrome 6.5 3.8 8.3 6.1 0.396 
Lethargy 5.7 7.7
a,b
 16.6
b
 3.2
a
 <0.0001 
Nausea/Vomiting 5.6 0.0
a,b
 1.7
b
 6.6
a
 0.005 
Neurological symptoms 8.5 11.5 4.6 9.3 0.051 
Osteoporosis 1.4 3.8
a,b
 3.7
b
 0.8
a
 0.001 
Previous abnormal histology 11.1 30.8
a
 7.1
b
 11.4
c
 0.001 
Reflux 12.2 0.0
a
 1.7
a
 14.8
b
 <0.0001 
Weight Loss 5.6 3.8 7.5 9.5 0.385 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Multinomial logistic regression of presenting characteristics 
Characteristic 
Ultra Short Celiac Disease (n=26) 
Conventional celiac 
disease (n=242) 
Compared to controls 
(n=1110) 
Compared to conventional 
celiac disease 
Compared to controls 
(n=1110) 
AOR P AOR p AOR P 
Age 
0.94  
(0.91 - 0.97) <0.0001 
0.97 
(0.94 ʹ 0.998) 0.03 
0.97  
(0.96 - 0.98) <0.0001 
Female Gender 
1.40  
(0.54 - 3.61) 0.49 
1.38  
(0.52  ? 3.65) 0.52 
1.01  
(0.72 - 1.42) 0.93 
Abdominal pain 
0.09  
(0.01 - 0.76) 0.03 
0.14  
(0.02  ? 1.29) 0.08 
0.61  
(0.38 - 0.99) 0.05 
Alternating 
bowel habit 
4.44  
(0.93 - 21.32) 0.06 
4.34  
(0.82  ? 23.00) 0.09 
1.02  
(0.40 - 2.59) 0.96 
Anaemia 
1.10  
(0.32 - 3.74) 0.88 
0.62  
(0.18  ? 2.18) 0.46 
1.77  
(1.11 - 2.82) 0.02 
Autoimmunity 
2.31  
(0.63 - 8.50) 0.21 
1.75  
(0.44  ? 6.92) 0.42 
1.32  
(0.67 - 2.58) 0.42 
B12 /folate 
/vitamin D 
deficiency 
0.77  
(0.16 - 3.76) 0.75 
0.72  
(0.14  ? 3.65) 0.69 
1.07  
(0.57 - 2.02) 0.82 
Bloating 
0.74  
(0.15 - 3.61) 0.71 
0.68  
(0.14  ? 3.71) 0.64 
1.09  
(0.64 - 1.87) 0.75 
Diarrhoea 
0.20  
(0.02 - 1.66) 0.14 
0.13 
(0.02  ? 1.10) 0.06 
1.53  
(1.00 - 2.33) 0.05 
Dyspepsia 
0.32  
(0.06 - 1.62) 0.17 
1.68  
(0.30  ? 9.49) 0.56 
0.18  
(0.10 - 0.36) <0.0001 
Family History 
1.98  
(0.50 - 7.91) 0.33 
0.69  
(0.17  ? 2.75) 0.60 
2.86  
(1.67 - 4.91) <0.0001 
IBS 
0.15  
(0.02 - 1.36) 0.09 
0.23  
(0.02  ? 2.20) 0.20 
0.64  
(0.35 - 1.17) 0.15 
Lethargy 
1.32  
(0.27 - 6.50) 0.73 
0.35  
(0.07  ? 1.73) 0.20 
3.74  
(2.19 - 6.37) <0.0001 
Nausea/Vomiting NS NS Ns NS 
0.34  
(0.12 -0.99) 0.05 
Neurological 
symptoms 
0.93  
(0.22 - 3.92) 0.93 
1.86  
(0.40  ? 8.73) 0.43 
0.50  
(0.25 - 1.01) 0.06 
Osteoporosis 
5.26  
(0.50 - 54.91) 0.17 
0.91  
(0.09  ? 9.62) 0.93 
5.81  
(2.09 - 16.15) 0.001 
Previous 
abnormal 
histology 
4.33  
(1.63 - 11.47) 0.003 
8.67  
(2.98 ʹ 25.25) <0.0001 
0.50  
(0.29 - 0.87) 0.01 
Reflux ns Ns Ns 0.98 
0.28  
(0.10 - 0.81) 0.02 
Weight Loss 
0.39  
(0.05 - 3.11) 0.37 
0.46  
(0.05  ? 3.74) 0.60 
0.87  
(0.48 - 1.55) 0.63 
 
Table 4: Analysis of absolute blood and DXA values in ultra-short celiac disease compared 
to conventional celiac disease and controls 
  
USCD (n=26) 
Conventional CD 
(n=242) 
Controls 
(n=136) 
p 
Multivariate analysis 
USCD compared to 
conventional CD 
Mean Median Mean Median Mean Median AOR p 
tTG xULN 
(All patients 
n=1378) 6.8 4.8
 a
 12.9 20
 b
 0.96 0.27
 c
 
<0.000
1 
0.91 
(0.84 - 0.98) 0.02 
Hemoglobin 13.8
 a
 14 13.6
 a
 13.8 13.9
 a
 13.8 0.43 
1.10 
(0.56 - 2.15) 0.88 
MCV 87.4
 a
 88.4 88.4
 a
 88.6 89.8
 b
 90.2 0.03 
0.95 
(0.84 - 1.07) 0.38 
B12 353.8 349.5
 a
 406.9 364
 a
 390.6 356
 a
 0.53 
1.00 
(0.99 - 1.00) 0.09 
Ferritin 63.9 45.5
 a,b
 61.2 34
 b
 66.5 50
 a
 0.03 
1.00 
(0.99 - 1.01) 0.87 
Folate 10.2 9.6
 a,b
 8.3 7.2
 b
 10.2 8.6
 a
 0.002 
1.17 
(1.03 - 1.35) 0.02 
Calcium 2.3 2.3
 a
 2.31 2.31
 a
 2.3 2.29
 a
 0.84 
7.33 
(0.02 - 
2446.7) 0.50 
ALT 30.9 17
 a
 27.3 21
 a
 22.7 18
 a
 0.05 
1.01 
(0.99 - 1.03) 0.56 
T-Score 
Spine -0.72
 a
 -0.8 -0.7
 a
 -0.7 na na 0.74 
0.65 
(0.296 - 1.46) 0.29 
T-Score Hip -0.32 -0.1
a
 -0.38 -0.3
a
 na na 0.99 
1.36 
(0.51 - 3.64) 0.54 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Comparison of relative blood and DXA values in ultra-short celiac disease 
compared to conventional disease and controls (figures with different superscript letters 
are significant at a P<0.05 level) 
 Percentage abnormality 
USCD CCD Control P 
Anemia 8.0 9.0 5.2 0.38 
Microcytosis 12.0 7.3 4.6 0.24 
Low B12 0.0 5.8 3.9 0.50 
Low Ferritin 13.6
a,b
 31.5
b
  16.7
a
 0.007 
Low Folate 3.8
a,b
 18.0
b
 6.3
a
 0.003 
Hypocalcemia 4.8 8.3 7.3 0.95 
Elevated ALT 16.0 17.0 12.9 0.54 
Osteopenia or worse 47.4 44.6 Na 1.0 
Osteoporosis 10.5 13.5 Na 0.76 
 
 
Table 6: Comparison of paired median blood values before and after a gluten free diet in 
Ultra-Short and Conventional Celiac Disease 
  
USCD Conventional Celiac Disease 
Pre-GFD Post-GFD p 
Pre-
GFD 
Post-
GFD p 
tTG xULN 4.97  0.87 0.006 20.0 0.87 <0.0001 
Hemoglobin 13.70 13.60 0.72 13.70 13.70 0.76 
MCV 87.30 88.20 0.88 89.20 90.20 0.13 
Calcium 2.26 2.36 0.03 2.32 2.32 0.35 
ALT 18.00 17.00 0.9 22.00 20.00 0.004 
B12 315.5 295.50 0.14 357 417.00 <0.0001 
Ferritin 41.0 34.00 0.05 31.5 50.50 <0.0001 
Folate 9.55 8.50 0.79 7.70 9.00 0.001 
 
 
  
Figure 1: CHAID decision tree for the diagnosis of celiac disease based on symptomatic 
presentation 
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